Profound Medical (PROF) to Release Quarterly Earnings on Thursday

Profound Medical (NASDAQ:PROF) will likely be posting its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Profound Medical to post earnings of ($0.24) per share and revenue of $4.8520 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Profound Medical (NASDAQ:PROF) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, meeting the consensus estimate of ($0.27). The firm had revenue of $5.98 million during the quarter, compared to analyst estimates of $10.53 million. Profound Medical had a negative net margin of 264.45% and a negative return on equity of 90.28%. On average, analysts expect Profound Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Profound Medical Stock Down 0.5%

PROF stock opened at $7.24 on Wednesday. The stock has a market capitalization of $262.92 million, a PE ratio of -5.12 and a beta of 0.73. Profound Medical has a 52 week low of $3.76 and a 52 week high of $8.95. The company has a quick ratio of 11.17, a current ratio of 12.52 and a debt-to-equity ratio of 0.07. The firm has a 50 day moving average of $6.40 and a 200 day moving average of $6.73.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PROF. Goldman Sachs Group Inc. grew its position in Profound Medical by 56.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,727 shares of the company’s stock worth $147,000 after purchasing an additional 6,787 shares during the period. Corsair Capital Management L.P. purchased a new stake in shares of Profound Medical in the fourth quarter worth about $208,000. Millennium Management LLC acquired a new stake in Profound Medical during the fourth quarter worth about $211,000. Quadrature Capital Ltd acquired a new stake in Profound Medical during the fourth quarter worth about $256,000. Finally, Hohimer Wealth Management LLC purchased a new position in Profound Medical during the fourth quarter valued at approximately $394,000. 47.86% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on PROF shares. Lake Street Capital raised their price target on shares of Profound Medical from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Profound Medical in a report on Friday, March 27th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Profound Medical presently has a consensus rating of “Hold” and a consensus price target of $12.00.

About Profound Medical

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.